April 13, 2010 (FinancialWire) — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) said members of its scientific teams will be reporting preclinical data from its novel Hedgehog pathway inhibitor program during the 2010 American Association of Cancer Research annual meeting being held in Washington, D.C. from April 17 through April 21, 2010.

Infinity says Hedgehog pathway inhibitor, IPI-926, is a potent, orally delivered, small-molecule drug candidate that has demonstrated significant anti-tumor activity in multiple preclinical cancer models. IPI-926 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.

Scheduled presentations for the program begin Tuesday, April 20, at 11:55 a.m. and two simultaneous programs on Wednesday, April 21, at 8.

Infinity is a drug discovery and development company that develops medicines for the treatment of cancer and related conditions. Infinity's programs include the inhibition of the Hsp90 chaperone system and the Hedgehog pathway and fatty acid amide hydrolase.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [cnfrncvntprsntn] [prsnttnsntt]